Home › Research › Brain scans and imaging
Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study
Yoichi Otomi, Takayoshi Shinya, Hideki Otsuka, Hiroto Kasai, Tomoki Matsushita, Yukiko Takaoka, Yuka Hiroshima, Tomoyasu Matsubara et al.. Japanese journal of radiology, 2026-07-27
Topic: Plasma and spinal-fluid biomarkers
Centiloid values significantly decreased from 52.3 ± 23.4 at baseline to - 5.6 ± 16.5 at follow-up, with a mean change of - 58.0 (p < 0.001). All patients showed a reduction in Centiloid values. In the flutemetamol group (n = 12), pons-referenced SUVr significantly decreased, while in the florbetapir group (n = 8), cerebellar-referenced SUVr also showed significant reductions (both p < 0.001). On visual assessment, 17 of 20 patients (85%) converted from amyloid-positive to amyloid-negative status after treatment. Serial amyloid PET demonstrated a substantial reduction in amyloid burden following donanemab treatment in this real-world cohort. Quantitative amyloid PET, particularly using Centiloid scaling, may be a useful tool for monitoring treatment response in clinical practice.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Otomi, Y., Shinya, T., Otsuka, H., Kasai, H., Matsushita, T., Takaoka, Y., et al. (2026). Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study. Japanese journal of radiology. https://doi.org/10.1007/s11604-026-02054-x
Vancouver
Otomi Y, Shinya T, Otsuka H, Kasai H, Matsushita T, Takaoka Y, et al. Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study. Japanese journal of radiology. 2026. doi:10.1007/s11604-026-02054-x. PMID: 42507054.
BibTeX
@article{otomi2026-42507054,
author = {Otomi, Yoichi and Shinya, Takayoshi and Otsuka, Hideki and Kasai, Hiroto and Matsushita, Tomoki and Takaoka, Yukiko and Hiroshima, Yuka and Matsubara, Tomoyasu and others},
title = {{Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study}},
journal = {Japanese journal of radiology},
year = {2026},
doi = {10.1007/s11604-026-02054-x},
pmid = {42507054},
url = {https://doi.org/10.1007/s11604-026-02054-x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Centiloid values significantly decreased from 52.3 ± 23.4 at baseline to - 5.6 ± 16.5 at follow-up, with a mean change of - 58.0 (p < 0.001).
- All patients showed a reduction in Centiloid values.
- In the flutemetamol group (n = 12), pons-referenced SUVr significantly decreased, while in the florbetapir group (n = 8), cerebellar-referenced SUVr also showed significant reductions (both p < 0.001).
- On visual assessment, 17 of 20 patients (85%) converted from amyloid-positive to amyloid-negative status after treatment.
- Serial amyloid PET demonstrated a substantial reduction in amyloid burden following donanemab treatment in this real-world cohort.
New to this subject? Start with our plain-English guide: Brain scans & tests →
Study details
- Participants12
- Evidence strengthModerate
How this study scored 55/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 31 of the 56 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Japanese journal of radiology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 1 / 4 | 12 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42507054) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 31 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 31 of the 56 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Brain scans and imaging
Also tagged “aducanumab”
332 studies in the library carry the topic tag “aducanumab”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.